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Short term toxicity studies are conducted in animals to provide information on major adverse effects typ-
ically at the maximum tolerated dose (MTD). Such studies are important from a scientiﬁc and ethical per-
spective as they are used to make decisions on progression of potential candidate drugs, and to set dose
levels for subsequent regulatory studies. The MTD is usually determined by parameters such as clinical
signs, reductions in body weight and food consumption. However, these assessments are often subjective
and there are no published criteria to guide the selection of an appropriate MTD. Even where an objective
measurement exists, such as body weight loss (BWL), there is no agreement on what level constitutes an
MTD. A global initiative including 15 companies, led by the National Centre for the Replacement, Reﬁne-
ment and Reduction of Animals in Research (NC3Rs), has shared data on BWL in toxicity studies to assess
the impact on the animal and the study outcome. Information on 151 studies has been used to develop an
alert/warning system for BWL in short term toxicity studies. The data analysis supports BWL limits for
short term dosing (up to 7 days) of 10% for rat and dog and 6% for non-human primates (NHPs).
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
1.1. Background
The pharmaceutical industry recognises the need to re-assess
the design and conduct of toxicity studies in animals as new
scientiﬁc practises and knowledge develop. The assessment in-
cludes the consideration of the ‘3Rs’, the replacement, reﬁnement
and reduction of animals in research (Russell and Burch, 1959),
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are performed to the most up to date scientiﬁc knowledge and that
opportunities for the 3Rs are identiﬁed.
Historically, the ﬁrst toxicity test performed in pharmaceutical
development was the acute toxicity study (Casarett and Doull’s
Toxicology, 1999). The main objective of this study was to identify
a single dose causing major adverse effects/life threatening toxic-
ity, which often involved an estimation of the minimum dose caus-
ing lethality. Since 2009, conventional acute toxicity studies are no
longer required to support clinical trials of pharmaceuticals in man
(ICH, 2009). This is a direct result of a collaboration of 18 compa-
nies led by the National Centre for the Replacement, Reﬁnement
and Reduction of Animals in Research (NC3Rs) and AstraZeneca.
Data were analysed from 70 compounds in a wide range of thera-
peutic areas and it was demonstrated that acute toxicity studies
had little value in assessing risk to humans (Robinson et al.,
2008). Additionally, acute toxicity studies are no longer used for
managing overdose of pharmaceuticals and have been found to
be of little value in treating human poisoning from chemicals. This
consensus was reached at a workshop held by the NC3Rs which
brought together clinicians, toxicologists, regulators and directors
of Poison Centres (Chapman et al., 2010; Robinson and Chapman,
2009). In the absence of acute toxicity data, the necessary informa-
tion can instead be obtained from short term studies (up to 7 days
daily dosing) that are already an existing part of the drug develop-
ment process. Such studies provide information on major adverse
effects that are observed at the maximum tolerated dose (MTD).
This dose is referred to as the MTD because the animal receiving
the test item would not tolerate adverse effects that may occur
at higher doses. The MTD is deﬁned as the highest dose that will
be tolerated within a given study for the study duration.
Deﬁning the MTD in the studies of shortest duration (up to
7 days) informs dose setting in subsequent toxicity studies and is
crucially important in the application of the 3Rs, since this reduces
the chances of larger numbers of animals that are used in regula-
tory studies being exposed to unanticipated suffering (NC3Rs/
LASA, 2009). The MTD is usually determined by parameters such
as clinical signs and reductions in body weight and food consump-
tion. However, there are no published criteria on the intensity and
duration of clinical signs that would optimise the selection of an
MTD, especially in studies of short duration. Body weight loss
(BWL) is an objective measurement and is often used as a primary
endpoint in these studies but there is no agreement on what level
of BWL constitutes an MTD, although cross company experience
indicates typical upper limits of between 15% and 25% loss. There-
fore, despite the crucial importance of deﬁning a short term MTD
from a scientiﬁc, regulatory and ethical perspective, variation ex-
ists across the industry and regulators on the interpretation of clin-
ical signs and BWL indicative of the MTD.
There are various publications that relate to animal study end-
points (FELASA, 1994; Morton, 2000; Morton and Grifﬁths, 1985;
Workman et al., 2010). In general, these publications recommend
a maximum upper BWL limit of 20%. However, these recommenda-
tions are not based on data sharing and do not address BWL in short
term toxicity studies speciﬁcally. For example, the Organisation for
Economic Co-operation and Development (OECD) guidance de-
scribes endpoints in toxicity studies, such as clinical signs, BWL,
and decreases in food consumption, that are indicators of severe
pain, distress, suffering, or impending death and therefore addresses
ﬁndings characterised as being above the limit of suffering that is
considered within the MTD range (OECD, 2000). Similarly, Morton
(2000) discusses the use of a clinical scoring system to indicate the
overall well-being of the animal and to establish humane endpoints.
However, this publication is more general, and recommends a tech-
nique that should be developed and tailored to the needs of the indi-
vidual study, and does not provide speciﬁc evidence-basedguidelines. Nevertheless, the examples presented by Morton
(2000) imposed an upper BWL limit of 20%, and suggest that
BWL may be an early indicator of adverse effects, often occurring
before the appearance of additional clinical signs. Correspondingly,
the Federation of European Laboratory Animal Science Associa-
tions (FELASA) working group report on pain and distress in ani-
mals contains examples of clinical signs and BWL that address
the range of mild, moderate and substantial severity animals
may experience during toxicity studies (FELASA, 1994). Further
to this, and in collaboration with the Laboratory Animal Science
Association (LASA), the NC3Rs has worked with an expert group
of toxicologists to develop guidance on dose level selection in reg-
ulatory general toxicology, stating that it is possible to deﬁne an
MTD in animal studies using clinical signs of moderate severity
(NC3Rs/LASA, 2009). The FELASA report suggests that up to 20%
BWL is acceptable under a moderate severity categorisation. How-
ever, this reduction in BWL is not evidence-based and there is no
deﬁnition of study duration or differentiation between rapid BWL
(as might occur in a short term toxicity study) and slower BWL,
more likely to be experienced during sub-chronic and chronic tox-
icity studies. The ICH Guideline S1C(R2) for dose selection for car-
cinogenicity studies of pharmaceutical states ‘no more than 10%
decrease in body weight gain relative to controls’ as one of the fac-
tors included in the deﬁnition of MTD (ICH, 2008). However, this is
a speciﬁc guideline for carcinogenicity studies and refers to weight
gain, rather than weight loss.
1.2. Working group objectives
The NC3Rs industry working group was initially established in
2003 to challenge the requirement for acute toxicity studies in
the development of newmedicines. In 2008, the group successfully
completed an objective of collecting an evidence base to demon-
strate that conventional acute toxicity studies did not add value
in the development of medicines.
For the past 4 years, the NC3Rs working group has continued
with further objectives of reﬁning endpoints within short term tox-
icity studies (up to 1 week in duration). Among a number of poten-
tial endpoints considered (including pain, clinical signs and
seizures), BWL was chosen as the most objective and quantiﬁable
endpoint and thus amenable to collecting data ontodevelop evi-
dence-based limits. The group currently represents 10 global phar-
maceutical companies and 5 contract research organisations (see
author afﬁliations) and is facilitated by the NC3Rs.
BWL is one of the few objective measures assessed in short term
toxicity studies, and is often the primary endpoint used in safety
assessment. Therefore, the main objective of this work was to
share data on BWL in toxicity studies following dosing of up to
7 days in duration, in rat, dog and non-human primates (NHPs).
The aims were to assess the treatment impact on the animals both
within studies of short duration and for dose setting in follow up
studies (typically with longer treatment duration), to review
whether limits for BWL could be reﬁned to improve animal wel-
fare. We set out to build an evidence-based upper limit for BWL
in 3 primary species used for safety assessment that could be used
in short term studies as part of the criteria for deﬁning the MTD.
To do this we asked the following questions:
(1) How does BWL relate to the MTD in short term studies?
(2) What happens in the study at BWL above certain thresholds
e.g. is the dosing stopped and/or do animals die prematurely
or require euthanasia?
(3) What impact does signiﬁcant BWL have on dose-selection
for follow up studies?
(4) Does BWL at MTD differ for different species, different study
durations, or for speciﬁc pharmacological subclasses?
Table 2
Deﬁnition of study types.
Study Type Deﬁnition
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within a given study?Study Type 1 Up to 3 days of dosing (including single dose
administration)
Study Type 2 Between 4 and 7 days of dosing
Study Type 3 The ﬁrst 7 days of dosing within a longer term
study (of up to 1 month in duration)2. Methods
A questionnaire was developed in order to collect information
on BWL over a short treatment duration (up to 7 days) (Table 1).
Wording of the questions was agreed upon in advance by all
respondents to avoid misinterpretation. All studies included had
undergone approval through local ethical review. Studies were
deﬁned by species: rat, dog or NHP, and also by the study type
(Table 2). Study type 1 was deﬁned as a study with up to 3 days
of dosing (including single dose administration). Study type 2
was deﬁned as a study with 4–7 days of dosing and study type 3
was deﬁned as the ﬁrst 7 days of dosing within any longer study
(e.g. 2–4 weeks). These studies may have been carried out for
variety of reasons including dose range ﬁnding, MTD determina-
tion or sub-chronic toxicology.
Respondents were asked to record BWL and to provide informa-
tion on what happened during the study (e.g. dosing was stopped,
animals died or required euthanasia), and as a consequence of the
study (e.g. dose was reduced in a follow up study). Consensus
within the working group was that the MTD was exceeded when
dosing either had to be stopped or if animals were lost from the
study, through premature death or euthanasia. Where we asked
for information on dosing decisions for any subsequent follow up
studies, this may have applied to repeat studies of similar duration,
as well as those of longer duration.
BWL was calculated for each individual animal as the percent-
age in weight lost from the pre-treatment weight. Data were col-
lected from studies with BWL >10% for rat and >6% for both dog
and NHP studies. BWL data were separated into 3 categories using
the maximum BWL recorded for each study; for rat these were 10–
15%, 16–20% and >20% BWL, for dog and NHP these were 6–10%,
11–15% and 16–20%. Since studies were identiﬁed using the max-
imum BWL recorded, it is possible that studies categorised in a
higher BWL category may also include animals with BWL at lower
severity levels. Respondents were also asked to specify whether
BWL was associated with any additional clinical signs recorded
in each individual animal. The nature of each speciﬁc clinical signTable 1
Questionnaire (for rat).was not recorded and therefore ‘the presence of additional clinical
signs’ encompass a range of signs with variable severity.
Data on the therapy area of the compound under study were
also collected from respondents and whether BWL was linked to
an expected pharmacological effect. For example, compounds with
a pharmacological action that interferes with biological processes
(such as many compounds in metabolic, endocrine or anti-inﬂam-
matory therapy areas) are likely to result in BWL. Additional infor-
mation that may be useful in the analysis was provided in the
comments ﬁeld e.g. differences or patterns of effect in low, med-
ium and high dose groups, food intake observations, weighing fre-
quency and vehicle effects.
Completed questionnaire tables were provided in conﬁdence by
individual companies and data were collated and anonymized be-
fore analysis by the working group.
We speciﬁcally examined whether there were any differences
between study types or BWL categories. We analysed further those
studies where the recorded BWL had no impact on the subsequent
study and whether there was a link between the dose selection for
subsequent work and the absence or presence of additional clinical
signs.
3. Results
3.1. Overall data
Data from 151 toxicity studies in rats, dogs and NHPs were col-
lected from 13 of the 15 listed pharmaceutical companies and con-
tract research organisations (Fig. 1). The data spanned a wide range
of therapeutic areas. In total, data were obtained from 90 rat, 48
dog and 13 NHP studies (Fig. 1A). Raw data for all studies collected,
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(Tables S1–S3). The most highly represented therapy areas were
oncology and central nervous system, corresponding to almost a
third or a quarter of the studies respectively (Fig. 1B); this was
approximately consistent between the different species (as shown
in Fig. 2A, Fig. 3A and Fig. 4A). Therapy area was not recorded for a
small number of studies (4 rat studies and 1 dog study).
The majority of studies were either type 2 or type 3 and there
were only a small number of the shorter term type 1 studies
(Fig. 1C). Therefore, study type 1 and 2 were combined and ana-
lysed together. These were separated from study type 3, as it was
thought that different criteria may have guided decisions in studies
of longer duration in comparison to the studies of up to 1 week in
duration. For example, a BWL that may be tolerated for up to aFig. 1. Total number of studies by (A) species (B) therapy area (C) study type and (D) by
for 146 of the 151 studies.
Fig. 2. Rat data. Total number of rat studies by (A) therapy area (B) study type (C) BWL ca
rat data collected; BWL >10%) and (E) sub-divided into BWL categories (10–15%, 16–20%
were divided into BWL categories based on the maximum BWL recorded for each studyweek may not be sustainable over the longer dosing periods of
up to a month. However, at this point it is important to reiterate
that, although type 3 studies could be up to 1 month in duration,
the type 3 data collected only refer to the ﬁrst 7 days of dosing.
In the majority of all studies BWL was associated with addi-
tional clinical signs in all animals (Fig. 1D). Consensus within the
working group was that the MTDwas exceeded when dosing either
had to be stopped or if animals were lost from the study, through
death or euthanasia. In most cases, when the dosing was stopped,
this was accompanied by animal death. Out of 151 studies, across
all species, there were only 5 cases where dosing was stopped in
the absence of euthanasia or premature death. We therefore exam-
ined whether the dosing was stopped and/or animals died
prematurely.the presence or absence of additional clinical symptoms. Therapy area was recorded
tegory and (D, E) by the presence or absence of additional clinical symptoms (for all
and >20%). Therapy area was only recorded for 86 of the 90 rat studies. Rat studies
.
Fig. 3. Dog data. Total number of dog studies by (A) therapy area (B) study type (C) BWL category and (D, E) by the presence or absence of additional clinical symptoms (for all
dog data collected; BWL >6%) and (E) sub-divided into BWL categories (6–10%, 11–15% and 16–20%). Therapy area was recorded for 47 of the 48 dog studies. Dog studies were
divided into BWL categories based on the maximum BWL recorded for each study.
Fig. 4. NHP data. Total number of NHP studies by (A) therapy area (B) study type (C) BWL category and (D, E) by the presence or absence of additional clinical symptoms (for
all NHP data collected; BWL >6%) and (E) sub-divided into BWL categories (6–10%, 11–15% and 16–20%). Therapy area was recorded for all NHP studies. NHP studies were
divided into BWL categories based on the maximum BWL recorded for each study.
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Data were collected from 90 rat studies (Fig. 2) where BWL
>10% was recorded. The majority of data (59 studies) were derived
from study type 2, with only small number of type 1 studies (7
studies). Just over a quarter of the studies (24/90) were study type
3 (Fig. 2B). Rat studies were divided into BWL categories using the
maximum BWL recorded for each study; BWL >20% was seen in 40
studies, 16–20% BWL occurred in 29 studies and 11–15% BWL in 21studies (Fig. 2C). These BWLs appeared to be fairly evenly distrib-
uted between the different study types.
Overall, MTD was exceeded in just over half of the rat studies;
dosing was stopped and/or animals died prematurely or were
euthanized in 50/90 studies with BWL >10% (Table 3). This was
more frequent with higher BWL (>20%), particularly in study type
3, where MTD (according to the working group consensus) was ex-
ceeded in all but one of the type 3 studies. To deﬁne an appropriate
cut off point for BWL in rat studies we ﬁrst analysed the differences
Table 3
Rat data. The number or percentage of rat studies in which MTD was exceededa and the number or percentage of studies in which the dose was reducedb in a subsequent study.
The data categorised by study type and BWL as indicated. Data was analysed above and below a 15% BWL threshold (10–15% vs. >15%).
Rat studies BWL (%) Study Type 1 + 2 Study Type 3 All studies
No. of studies % No. of studies % No. of studies %
MTD exceededa >20 14/27 52 12/13 92 26/40 65
16–20 9/24 38 4/5 80 13/29 45
10–15 7/15 47 4/6 67 11/21 52
>15 23/51 45 16/18 89 39/69 57
All data (>10) 30/66 45 20/24 83 50/90 56
Dose subsequently reducedb >20 21/27 78 12/13 92 33/40 83
16–20 17/24 71 5/5 100 22/29 76
10–15 11/15 73 5/6 83 16/21 76
>15 38/51 75 17/18 94 55/69 80
All data (>10) 49/66 74 22/24 92 71/90 79
a MTD was considered to have been exceeded when dosing either had to be stopped or if animals were lost from the study, through death or euthanasia.
b Where a subsequent study was not carried out we asked respondents to comment on whether the same dose that caused the initially observed BWL would have been
used again. Therefore, in some cases, this data represents a hypothetical dose reduction in the subsequent study.
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animals were lost from the study in almost all of the type 3 studies
with BWL >15% (16/18 studies), and in two thirds of the type 3
studies with BWL 10–15% (4/6 studies). For study type 1 and 2,
there was no difference; MTD was exceeded in just under half of
the studies, whether BWL was >15% or in the 10–15% category.
We then asked what happened to dose levels in any subsequent
studies. Follow up studies were carried out in 30/90 studies and
the dose was reduced in 24/30 cases. When no further studies were
carried out we asked respondents to comment on whether the
same dose that caused the initially observed BWL would have been
used again. In 47/60 cases it was predicted that the dose that
caused maximum BWL in the initial study would have been low-
ered in the follow up study, if one were to have been performed.
Taken together, the dose was reduced or would have been reduced
in 71/90 studies where BWL was >10%, and of these, the dose was
more likely to be reduced in study type 3 than in study type 1 or 2.
For study types 1 and 2 dose reduction occurred in a similar pro-
portion of studies for each BWL category, whereas dose reduction
was somewhat more likely to occur at a higher percent BWL
(>15%) for study type 3 (Table 3).
The dose was not (or was not predicted to have been) reduced
in 19/90 follow up studies, with the majority of these being type
2 studies (17/19), and the remaining two being study type 3.
BWL was linked to the expected pharmacology in 15/19 of cases
where the dose would not have been reduced, whereas overall
BWL was linked to the expected pharmacology in 36/90 studies
(79% vs. 40%).
In rat studies, BWL was associated with additional clinical signs
in 80/90 studies, and in cases where BWL was >20% there was al-
ways at least one animal within that dose group that displayed
additional clinical signs (Fig. 2D). In fact, in 37/40 studies with
>20% BWL, additional clinical signs were associated with all ani-
mals (Fig. 2E). Of the 90 rat studies in total, there were only 14
studies which included at least one rat with BWL >10% that did
not display any clinical signs, and in 4 of these cases other animals
were identiﬁed in the same study group that did display additional
clinical signs (Fig. 2D).3.3. Dog data
Data were collected from 48 dog studies (Fig. 3) where BWL >6%
was recorded. Two thirds of the dog studies were type 3, and a
quarter of studies were type 2. Only 4 studies were study type 1
(Fig. 3B). Dog studies were divided into BWL categories using the
maximum BWL recorded for each study; BWL of 16–20% was seenin 21 studies, 11–15% in 19 studies and 6–10% in 8 studies (Fig. 3C).
Although the highest BWL (16–20%) was not observed in any of the
type 1 studies, the rest of the BWL categories were evenly distrib-
uted between study types.
Dosing was stopped and/or animals were euthanized or died
prematurely in over half the studies with BWL >6% (Table 4).
Although there was little difference between study types overall
(with MTD being exceeded in 56% of study types 1 and 2 combined
compared to 59% of study type 3), this was more likely to occur at
the highest percent BWL for study type 3 than in study types 1 and
2, occurring in 12/15 type 3 studies with 16–20% BWL compared to
only a third (2/6) of type 1 and 2 studies displaying 16–20% BWL.
To deﬁne an appropriate BWL limit for short term MTD studies, we
analysed the difference between studies with BWL above or below
a 10% threshold. As there were a limited number of studies where
BWL fell in the 6–10% BWL category we were unable to reliably
examine the differences between study types. Overall, dosing
was stopped and/or animals died, or required euthanasia in 3/8
studies with 6–10% BWL, compared to 25/40 of studies where
BWL was >10% (38% vs. 63%).
In general, dosing was reduced, or would have been reduced, in
42/48 studies with BWL >6%, including in all type 1 and 2 studies.
In study type 3, the dose was more likely to have been reduced if
BWL was above 10%; dose was reduced in 23/27 of type 3 studies
with BWL >10%, compared to 3/5 cases with 6–10% BWL (Table 4).
The dose was not (or was not predicted to have been) reduced in
6/48 follow up studies. BWL was linked to the expected pharma-
cology in one third (2/6) of the studies where the dose would not
have been lowered, whereas overall BWL was linked to the
expected pharmacology in 9/48 studies (19%).
BWL was associated with additional clinical signs in 44/48 stud-
ies with dogs that had BWL >6%. However, in 5 of these studies not
all dogs displayed clinical signs (i.e. there were also other dogs in
the same study group without any additional clinical signs)
(Fig. 3D). Only 4 studies included dogs where all animals displayed
BWL (>6%) without any additional clinical signs (Fig. 3E). Diet was
supplemented in 8/48 studies, all of which displayed BWL > 10%.3.4. Non-human primate data
The dataset for NHPs was limited; data were collected from 13
studies in total where BWL >6% was recorded. Almost one third of
the data were from type 2 studies, and only one type 1 study was
included. The remaining studies were type 3, where data were de-
rived from the ﬁrst 7 days of studies of longer duration, up to a
maximum of 1 month in duration (Fig. 4B). NHP studies were
Table 4
Dog data. The number or percentage of dog studies in which MTD was reached or exceededa and the number or percentage of studies in which the dose was reducedb in a
subsequent study. The data categorised by study type and BWL as indicated. Data was analysed above and below a 10% BWL threshold (6–10% vs. >10%).
Dog studies BWL (%) Study Type 1 + 2 Study Type 3 All studies
No. of studies % No. of studies % No. of studies %
MTD exceededa 16–20 2/6 33 12/15 80 14/21 67
11–15 4/7 57 7/12 58 11/19 58
6–10 3/3 100 0/5 0 3/8 38
>10 6/13 46 19/27 70 25/40 63
All data (>6) 9/16 56 19/32 59 28/48 58
Dose subsequently reducedb 16–20 6/6 100 12/15 80 18/21 86
11–15 7/7 100 11/12 92 18/19 95
6–10 3/3 100 3/5 60 6/8 75
>10 13/13 100 23/27 85 36/40 90
All data (>6) 16/16 100 26/32 81 42/48 88
a MTD was considered to have been exceeded when dosing either had to be stopped or if animals were lost from the study, through death or euthanasia.
b Where a subsequent study was not carried out we asked respondents to comment on whether the same dose that caused the initially observed BWL would have been
used again. Therefore, in some cases, this data represents a hypothetical dose reduction in the subsequent study.
Table 5
Non-human primate data. The number or percentage of NHP studies in which MTD was reached or exceededa and the number or percentage of studies in which the dose was
reducedb in a subsequent study. The data categorised by study type and BWL as indicated. Data was analysed above and below a 10% BWL threshold (6–10% vs. >10%).
NHP studies BWL (%) Study Type 1 + 2 Study Type 3 All studies
No. of studies % No. of studies % No. of studies %
MTD exceededa 16–20 0/1 0 2/2 100 2/3 67
11–15 1/2 50 3/4 75 4/6 67
6–10 2/2 100 0/2 0 2/4 50
>10 1/3 33 5/6 83 6/9 67
All data (>6) 3/5 60 5/8 63 8/13 62
Dose subsequently reducedb 16–20 1/1 100 2/2 100 3/3 100
11–15 1/2 50 4/4 100 5/6 83
6–10 2/2 100 2/2 100 4/4 100
>10 2/3 67 6/6 100 8/9 89
All data (>6) 4/5 80 8/8 100 12/13 92
a MTD was considered to have been exceeded when dosing either had to be stopped or if animals were lost from the study, through death or euthanasia.
b Where a subsequent study was not carried out we asked respondents to comment on whether the same dose that caused the initially observed BWL would have been
used again. Therefore, in some cases, this data represents a hypothetical dose reduction in the subsequent study.
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each study; a maximum BWL of 16–20% was observed in 3 studies,
11–15% BWL occurred in 6 studies, which included the single type
1 study, and BWL of 6–10% was seen in 4 studies (Fig. 4C). Type 2
studies included 2 studies with 6–10% BWL, and one of each of the
higher percent BWL categories. The majority of type 3 studies dis-
played BWL >10%.
Dosing was stopped and/or animals were euthanized, or died
prematurely in 8/13 studies with BWL >6% (Table 5). Due to the
limited number of studies it was difﬁcult to compare study types
and/or the different BWL categories.
A followupstudywascarriedout for6/13of studies, and thedose in
the follow up study was reduced in all 6 studies. When another study
wasnot carried outwe asked respondents to comment onwhether the
same dosewould have been used again. In 6/7 followup studies it was
predicted that the dose would have been lowered in the next study.
Therewas only one casewhere the dosewouldnot have been lowered.
In this study a BWL of 13%was observed in one animal and therewere
no other clinical signs linked to the treatment.
Overall, BWL was associated with additional clinical signs in 11/
13 NHP studies with BWL >6% (Fig. 4D and E). Only 2 studies exhib-
ited BWL in the absence of additional clinical signs. One of these
studies was the study mentioned above, where the dose would
not have been reduced, while renal toxicity was indicated in sub-
sequent histo- and clinical pathology for the other study that did
not display any additional clinical signs. Additional clinical signs
were recorded in all NHPs with 16–20% BWL. Only 1/13 NHP stud-ies indicated that BWL was linked to expected pharmacology. Diet
was supplemented in 3/13 NHP studies, all of which displayed
>10% BWL.4. Discussion
4.1. General discussion
The aim of the NC3Rs working group was to build an evidence
base to deﬁne an upper limit for BWL that could be used in short
term studies (up to 1 week in duration) as part of the criteria for
deﬁning the MTD. The consensus was that dosing was deemed
too high (i.e. the MTD had been exceeded) if the dosing had to be
stopped during the study or if animals died prematurely or re-
quired euthanasia throughout the study. We collected data from
13 pharmaceutical companies and contract research organisations
for 3 species (rat, dog and NHP) and examined how BWL related to
the MTD over a short duration of dosing, and what impact this BWL
had on any subsequent studies. Since the data were supplied from
a wide range of global pharmaceutical and contract research
organisations, it is assumed that the data are representative of gen-
eral toxicity studies industry-wide. However, since data were se-
lected by individuals there is a possibility that it could be subject
to bias, beyond our level of control.
The data gathered from across different organisations
showed similar results and has allowed us to make evidence-based
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rats, dogs and NHPs (speciﬁc recommendations for each species
will be discussed in more detail below). However, we realise that
it is difﬁcult to make recommendations based on BWL alone, and
that it is important for our recommendations to build on the cur-
rent guidelines for good practise in regulatory toxicology. A well
designed and implemented toxicology study involves understand-
ing of the basic science e.g. the pharmacological target, the likely
toxicological ﬁndings and the clinical application of the test item.
Interactive study management is essential to ensure the scientiﬁc
objectives are achieved whilst minimising the impact of any harm-
ful effects on the animals. Regular monitoring of clinical signs and
other data, such as body weight and food/water consumption, im-
parts greater understanding of the adverse effects and allow
adjustments to study design, dosing levels and/or humane end-
points to be made if appropriate. For example, early observation
of inappetance or BWL can allow appropriate intervention, includ-
ing allowing food to be available for longer periods of time, modi-
fying the food or the way it is presented to the animals to
encourage appetite (e.g. moistening dry diet or offering supple-
ments) or by reducing the dose level, stopping dosing or humane
euthanasia. Therefore, for each species, we have devised a decision
tree which takes additional criteria into account, such as the pres-
ence of clinical signs and/or the expected pharmacology, to recom-
mend BWL limits which will reﬁne short term toxicity studies
(Figs. 5–7).
The decision tree recommends a BWL limit for each species that
should act as a warning that MTD is near; BWL >10% for rat and
dog and BWL >6% for NHP (Figs. 5–7). If additional clinical signs
are observed in any animal above this threshold, then we would
recommend that the dose is too high and that the MTD has been
reached. However, in the absence of clinical signs it is important
to consider whether BWL is an ‘on-target’ or ‘off-target’ effect
(i.e. is BWL linked to the expected pharmacology). In cases where
BWL is not linked to the expected pharmacology (i.e. BWL is an
off-target effect), we recommend that MTD is near and that ani-Fig. 5. Rat decision tree, with a recommended alert/warning system to trigger when BWL
the expected pharmacology into account to make recommendations for when MTD is nea
tree shows how our data currently ﬁts into these recommendations (ﬁgures shown
recommendations. In our dataset the dose was reduced in 71/90 rat studies with BWL >1
studies with BWL >10%.mals continue to be monitored closely for additional clinical signs.
The only circumstance where a BWL higher than the recommended
limit is likely to be acceptable is if BWL is linked to the expected
pharmacology and there are no other associated clinical signs. In
our dataset, we have shown that this situation rarely takes place,
occurring in only 7 of the 151 studies analysed (less than 5% of
the data collected) (Figs. 5–7). Nevertheless, in accordance with
good practise guidelines, animals should be closely monitored for
adverse effects, and careful consideration should be given as to
whether the observed level of BWL is justiﬁed. The recommenda-
tions are not intended to overrule study director experience and
judgement.
It is important to note that our recommendations refer to short
term toxicity studies of up to 1 week in duration, and that there
may be different criteria for setting BWL in longer term studies.
For example, amarked BWLwhich occurs over a shorter time period
is less acceptable than the same BWL over a longer time period. In
terms of the data we collected, the study type and duration is likely
to have had an inﬂuence on the dosing decisions and/or interven-
tionsmadeduring the studies. Type1and2 studies are of short dura-
tion (up to a maximum of 1 week of dosing), whereas the data for
study type 3 represents the ﬁrst 7 days of a longer term study (up
to 1 month in duration). Therefore, dosing decisions thatweremade
for study type 3 may have been based on longer-term implications
i.e. so that any BWL observedwould be sustainable for the full dura-
tion of the study, to avoid having to terminate the dose group early
due to excessive BWL. On the other hand, for study types 1 and 2,
intervention (dosing stopped and/or euthanasia) may be less likely
during the study, as the study will only be short term, even if the
dose would then be subsequently reduced in the next study. This
is reﬂected in our ﬁnding that theMTDwasmore likely to have been
exceeded at higher percent BWL in study type 3.
There are two areas in which there may be an assumption that
BWL is more acceptable; where BWL is linked to the expected
pharmacology (discussed above) and for therapeutic targets for
oncology. Due to the aggressive nature of oncology treatments inis >10%. The decision tree takes additional considerations such as clinical signs and
r and when dosing should be stopped or reduced in subsequent studies. The decision
in brackets) and the potential for reﬁned MTD studies by uptake of these new
0%. Using our new recommendations the dose would have been reduced in 83/90 rat
Fig. 6. Dog decision tree, with a recommended alert/warning system to trigger when BWL is >10%. The decision tree takes additional considerations such as clinical signs and
the expected pharmacology into account to make recommendations for when MTD is near and when dosing should be stopped or reduced in subsequent studies. The decision
tree shows how our data currently ﬁts into these recommendations (ﬁgures shown in brackets) and the potential for reﬁned MTD studies by uptake of these new
recommendations. In our dataset the dose was reduced in 36/48 dog studies with BWL >10%. Using our new recommendations the dose would have been reduced in 39/40
dog studies with BWL >10%.
Fig. 7. NHP decision tree, with a recommended alert/warning system to trigger when BWL is >6%. The decision tree takes additional considerations such as clinical signs and
the expected pharmacology into account to make recommendations for when MTD is near and when dosing should be stopped or reduced in subsequent studies. The decision
tree shows how our data currently ﬁts into these recommendations (ﬁgures shown in brackets) and the potential for reﬁned MTD studies by uptake of these new
recommendations. In our dataset the dose was reduced in 12/13 NHP studies with BWL >6%. Using our new recommendations the dose would have been reduced in all (13/
13) NHP studies with BWL >6%.
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may be more readily accepted. Therefore, in animal studies for
oncology, it is seen necessary to push the severity limit to explore
the more severe side effects. As a result, it may be that BWL in ani-
mal studies has traditionally been considered more acceptable in
this area. Our data challenges these assumptions, as the data col-
lected here includes a large proportion of oncology compounds
(accounting for almost one third of the dataset). Therefore, our rec-
ommendations apply to all therapy areas, including oncology. With
regard to the oncology compounds included in this study, the
majority of these were administered by daily dosing, but a small
number of studies involved cyclical dosing (9/48 oncology com-pounds). Due to the nature of cyclical dosing, which may allow
time for recovery and weight gain between cycles, different criteria
may apply. Therefore, our recommendations relate to daily dosing
within short term toxicity studies.
Across all 3 species, MTD was exceeded in just over half of all
studies, and in subsequent studies the dose was reduced (or would
have been reduced) in the majority of studies overall. For the pur-
poses of our analysis, MTD was deﬁned as having been exceeded if
the dosing had to be stopped or if animals died prematurely or re-
quired euthanasia during the study. We have used the objective
measure of BWL to determine whether the MTD (using the deﬁni-
tion described above) has been exceeded. We also incorporated the
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add value to our practical advice on how to determine an MTD.
Our ﬁndings are used to make recommendations to reﬁne BWL
limits in short term toxicity studies.
We also took into account an additional aim of an MTD study,
which is to determine the dose for the subsequent studies.
Although the dosing was reduced in the majority of subsequent
studies overall, there were a number of exceptions, which will be
discussed in more detail for each species below. In general these
exceptions were studies where the MTD had not yet been exceeded
(in terms of whether the dosing was stopped or animals were lost
from the study) and/or where the expected pharmacology of the
compound was thought to result in BWL. In addition, these studies
were less likely to have animals showing additional clinical signs.
4.2. Rat – 10% BWL limit is sufﬁcient to deﬁne the MTD
In rat, the MTD was reached in just over half of the studies with
BWL >10%, although for subsequent studies the dose was reduced
or would have been hypothetically reduced in a larger proportion
of studies (71/90). Therefore, if the objective is to set the dose for
a follow up study, particularly if this is of longer duration, there
is no need to go higher than 10% BWL in the shorter term study.
There were only 19 exceptions where BWL was >10%, but where
the dose would not have been reduced in a subsequent study.
In 15 of the 19 studies (79%) where dosing would not have been
reduced BWL was linked to the expected pharmacology. This is
compared to 25 of the 71 studies (35%) where the dosing was sub-
sequently reduced, which suggests that BWL may be better toler-
ated if it is linked to the expected pharmacology. Similarly, BWL
appears to be better tolerated in studies where there is an absence
of additional clinical signs; no additional clinical signs were re-
ported in 6 of the 19 studies (32%) where the dose was not reduced,
compared to only 4 of the remaining 71 studies (6%) which would
have reduced dosing. In general, studies in which the dose was not
reduced were more likely to have BWL that was linked to the ex-
pected pharmacology, and were less likely to exhibit additional
clinical signs or require intervention, than studies where the dose
was consequently reduced. Interestingly, if we look back at our ini-
tial MTD deﬁnition above, the MTD did not appear to have been ex-
ceeded in 18 out of these 19 exceptions; dosing was not stopped
and animals were not euthanized and did not die prematurely.
In the one exception above where the dose would not have been
reduced despite the fact that it appears the MTD had been reached
or exceeded (dosing was stopped and an animal either died or re-
quired euthanasia), all animals exhibited >20% BWL with addi-
tional clinical signs. A subsequent study was carried out using
the same dose, but animals required premature euthanasia prior
to the end of the study, due to continued BWL. If our recommenda-
tions had been followed, this situation could have been avoided.
This illustrates the difﬁculty of not having clear accepted criteria
for MTD as decisions can be subjective. In short, if animals exhibit
high levels of BWL, if they display additional clinical signs, if the
dosing has to be stopped, or if animals die prematurely or require
euthanasia, then they have exceeded their MTD and require a re-
duced dose in subsequent studies. Introducing an evidence-based
decision tree to guide discussions during the study conduct (as
illustrated in Fig. 5) will help reduce the possibility of the situation
such as the one described above occurring in future.
Since we saw little difference between deﬁning the MTD at be-
tween 10% and 15% BWL or >15% and that BWL >10% rarely oc-
curred in the absence of additional clinical signs, we are
recommending an alert/warning system that MTD is reached or
is very near at 10% BWL within a week in rats. We have produced
a decision tree showing the impact of using 10% as the maximum
BWL in these studies (Fig. 5). The decision tree takes these addi-tional considerations into account and shows situations where
slightly higher BWL may be acceptable e.g. no additional clinical
signs and an expected pharmacology. However, we recommend
that even for these exceptions BWL >15% is usually not necessary.
We have shown how data from our existing studies currently ﬁt
those recommendations; for BWL that exceeds 10% the dose was
reduced, or would have been reduced, in 71 of the 90 studies. Using
our new recommendations, this would have risen to a dose reduc-
tion in 83 of the 90 studies (78% vs. 92%).
4.3. Dog – 10% BWL limit is sufﬁcient to deﬁne the MTD
In dog, BWL >6% were recorded. The MTD was exceeded in over
half of the studies and the dose would have been subsequently re-
duced in a follow up study for all but 6 of the studies in total. In the
6 studies where the dose would not have been reduced 4 studies
displayed >10% BWL. For 2 of these 4 compounds, BWL was linked
to the expected pharmacology. Additional clinical signs were seen
in 4 of the 6 studies (67%) where the dose would not have been re-
duced, compared to 40 of the 42 studies (95%) where the dose was
subsequently reduced. Although this is a more limited dataset,
these ﬁndings are similar to the rat data, where studies in which
dosing was not reduced were more likely to be associated with
the expected pharmacology, and were less likely to display addi-
tional clinical signs. Similarly, if we also look back at our initial
MTD deﬁnition, the MTD was not exceeded in 5 out of the 6 excep-
tions, where dosing was not reduced. In some studies an additional
intervention occurred; the diet was supplemented in 8 of the 48
dog studies, all of which displayed BWL >10%.
In order to deﬁne a threshold for an appropriate BWL limit we
analysed the difference between studies where BWL was above
or below a 10% BWL limit. MTD was reached more often when
BWL was >10% and the dose was also more likely to have been re-
duced in these studies. The data indicates that there is evidence for
regarding 10% BWL as the upper limit for dogs in short term stud-
ies of up to 7 days in duration. There is no apparent scientiﬁc value
in going higher than 10% BWL to validate dose selection for follow
up studies when the compound is progressing further into non-
clinical development. However, the dataset for the lower BWL cat-
egory was limited, with only 8 studies displaying a maximum BWL
of 6–10%, and if a larger evidence base was collected, it would have
been possible to determine whether a lower limit could have been
set. The decision tree in Fig. 6 shows our recommendation for a 10%
BWL limit in MTD studies using dogs, as well as additional factors
to consider, such as additional clinical signs and expected pharma-
cology, and shows how data from our existing studies currently ﬁt
those recommendations. For BWL that exceeds 10% the dose was
reduced, or would have been reduced in 36 of the 40 cases. Using
our new recommendations, this would have risen to dose reduc-
tions in 39 of the 40 studies with BWL >10% (90% vs. 98%). How-
ever, for short term duration we would recommend that BWL of
6% should act as a warning sign that MTD is near, and that BWL
should not exceed 10%.
4.4. Non-human primates – 6% BWL limit is sufﬁcient to deﬁne the
MTD
BWL >6% was recorded for NHPs. Although we had a more lim-
ited dataset for NHPs, we saw that the MTD was reached in the
majority of studies with BWL >6%, and that the dose was reduced
(or was predicted to have been reduced) in all but one study. In this
one exception, a BWL of 13% was recorded in one animal, and this
was not thought to be caused by the test article but to locomotor
problems (limping and decreased activity). Similar to the excep-
tions in rat and dog studies, the other animals in this study did
not show any additional clinical signs. In some studies an
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of the 13 NHP studies where BWL was >6%.
In general, a BWL >6% was associated with additional clinical
signs, occurring in 11 of the 13 NHP studies. Only 2 studies exhib-
ited BWL in the absence of additional clinical signs, one of which
only had BWL of 7% but was found to have renal toxicity in subse-
quent histo- and clinical pathology. Therefore, although the sample
size is small, it can be concluded that intervention (by diet supple-
mentation, stopping of dosing and/or euthanasia) is common prac-
tise for NHPs when BWL >6% is observed, and that BWL >6% rarely
occurs without additional clinical signs. However, there was insuf-
ﬁcient evidence to enable comparisons between the different study
types. Similarly, since there was only one compound with a phar-
macology that was thought to result in BWL, we cannot be sure
what inﬂuence this may have had on the decision making process.
For this compound the dose was still reduced even though the MTD
had not been exceeded, although BWL of 11–15% was observed and
all animals displayed additional clinical signs.
The sample size for NHP studies is small. Nevertheless, the
information does indicate that >6% BWL should act as a warning
that MTD is near in short term toxicity studies in NHPs of up to
1 week in duration. The decision tree in Fig. 7 shows our recom-
mendation for a BWL limit of 6% in NHPs, and also takes into ac-
count additional factors such as the presence of clinical signs. In
our dataset, when BWL was >6%, the dose was reduced, or would
have been hypothetically reduced in 12 of the 13 NHP studies.
Using our new recommendations, this would have risen to all 13
NHP studies (92% vs. 100%).
Physiologically, there are several reasons why NHPs may toler-
ate BWL less well than the other species tested. Since rats have a
very long growth period, BWL is a sensitive parameter for toxicity.
However, as rats are generally very robust, they tolerate BWL fairly
well over a period of time. Dogs, as carnivores, are physiologically
well prepared to deal with periods of feed restriction and subse-
quent BWL and, since adult animals show only little body weight
gain, they tolerate BWL reasonably well over a period of time. In
addition, due to their close connection to humans, clinical signs
are generally easy to observe in dogs, so that assessment of general
toxicity by combining BWL and clinical signs is feasible. For NHPs,
the situation is slightly different. NHPs are fairly sensitive to re-
duced food intake, which may be associated with BWL. The fact
that >6% BWL was generally associated with clinical signs is a rel-
atively severe ﬁnding, as NHPs have a strict hierarchy, and gener-
ally try not to show weakness in their social group.5. Conclusions
Employment of an evidence-based approach has allowed us to
recommend BWL limits for rats, dogs and NHPs in short term
MTD studies of up to 1 week in duration. The recommendations
take into account the presence or absence of additional clinical
signs and (in the absence of additional clinical signs) also the ex-
pected pharmacological action of the candidate drug. Our data
showed that there was little scientiﬁc value in exceeding 10%
BWL in 7 days for rat and dog and that this level of BWL was usu-
ally associated with additional clinical signs, resulting in a reduc-
tion in dose levels for subsequent studies. For NHPs, a lower BWL
limit of 6% in 7 days was recommended, based on the results from
NHP studies, which may reﬂect physiological differences between
species, and the greater impact of BWL on NHPs.
These recommendations represent a signiﬁcant reﬁnement
which has the potential to impact on thousands of animals world-
wide. We have recommended a BWL limit that is substantially
lower than the existing FELASA guidance which suggests an upper
limit of 20% BWL (FELASA, 1994), which will lead to a reduction inBWL limits based not only on current guidelines, but on current
practise in the pharmaceutical industry (based on data supplied
in this publication). The FELASA guidelines have limitations when
applying to speciﬁc areas of research, the recommendations were
not based on regulatory toxicology and do not specify study dura-
tion. Study duration in particular will have an inﬂuence on what
may be an acceptable BWL. For example rapid BWL of 15% occur-
ring within a short time frame (e.g. 3 days) may not be sustainable
over longer time periods, whereas gradual BWL of 15% over a long-
er time period (e.g. 2 weeks) may enable the same BWL to be tol-
erated. In addition, our recommendations also build on current
OECD guidance, which describes the recognition, assessment and
use of clinical signs as humane endpoints for experimental animals
which have already exceeded MTD (OECD, 2000), rather than to
indicate when MTD is near or when it has been reached.
Our recommendations are speciﬁc for short term toxicity stud-
ies (up to 1 week in duration) in regulatory toxicology and are sup-
ported by all members of the working group, which include
representatives from 10 global pharmaceutical companies and 5
contract research organisations. Use of these recommendations
will reﬁne the use of animals in short term MTD studies because
animals will experience less adverse effects. The objective ap-
proach we have taken will also enable more global acceptance of
the deﬁnition of an MTD.
In addition to regulatory toxicology for pharmaceuticals, our
evidence-based approach may be translated to other areas e.g.
chemicals, pharmacology, efﬁcacy (oncology, CNS, inﬂammation),
although this may not necessarily apply to very speciﬁc areas such
as food additives. Further work would involve speciﬁc data collec-
tion to determine objective, reﬁned and more humane endpoints in
individual research areas.
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